Evaluating cardiac risk: exposure response analysis in early clinical drug development

The assessment of a drug’s cardiac liability has undergone considerable metamorphosis by regulators since International Council for Harmonization of Technical Requirement for Pharmaceuticals for Human Use E14 guideline was introduced in 2005. Drug developers now have a choice in how proarrhythmia ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Grenier, Julie, Paglialunga, Sabina, Morimoto, Bruce H, Lester, Robert M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5912368/
https://www.ncbi.nlm.nih.gov/pubmed/29713203
http://dx.doi.org/10.2147/DHPS.S133286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5912368/
https://www.ncbi.nlm.nih.gov/pubmed/29713203
http://dx.doi.org/10.2147/DHPS.S133286

Ejemplares similares